Barclays’s MediciNova MNOV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $223K | Buy |
162,900
+123,500
| +313% | +$187K | ﹤0.01% | 3628 |
|
|
2025
Q4 | $51.6K | Sell |
39,400
-49,215
| -56% | -$67.9K | ﹤0.01% | 4736 |
|
|
2025
Q3 | $113K | Sell |
88,615
-19,385
| -18% | -$25.1K | ﹤0.01% | 4576 |
|
|
2025
Q2 | $141K | Buy |
108,000
+33,900
| +46% | +$47.5K | ﹤0.01% | 4479 |
|
|
2025
Q1 | $108K | Sell |
74,100
-21,500
| -22% | -$38K | ﹤0.01% | 4376 |
|
|
2024
Q4 | $201K | Buy |
95,600
+12,800
| +15% | +$25K | ﹤0.01% | 4306 |
|
|
2024
Q3 | $174K | Sell |
82,800
-400
| -0.5% | -$592 | ﹤0.01% | 4363 |
|
|
2024
Q2 | $120K | Hold |
83,200
| – | – | ﹤0.01% | 3822 |
|
|
2024
Q1 | $121K | Sell |
83,200
-8,100
| -9% | -$11.5K | ﹤0.01% | 4365 |
|
|
2023
Q4 | $137K | Sell |
91,300
-12,500
| -12% | -$22.6K | ﹤0.01% | 4552 |
|
|
2023
Q3 | $217K | Sell |
103,800
-8,600
| -8% | -$20K | ﹤0.01% | 3256 |
|
|
2023
Q2 | $259K | Sell |
112,400
-26,700
| -19% | -$58.8K | ﹤0.01% | 3122 |
|
|
2023
Q1 | $300K | Sell |
139,100
-9,300
| -6% | -$21.3K | ﹤0.01% | 3575 |
|
|
2022
Q4 | $304K | Sell |
148,400
-9,900
| -6% | -$21.9K | ﹤0.01% | 3617 |
|
|
2022
Q3 | $343K | Sell |
158,300
-22,900
| -13% | -$53K | ﹤0.01% | 2895 |
|
|
2022
Q2 | $458K | Sell |
181,200
-3,400
| -2% | -$8.87K | ﹤0.01% | 2930 |
|
|
2022
Q1 | $493K | Buy |
184,600
+11,800
| +7% | +$28.9K | ﹤0.01% | 2918 |
|
|
2021
Q4 | $463K | Buy |
172,800
+18,784
| +12% | +$62.8K | ﹤0.01% | 3241 |
|
|
2021
Q3 | $584K | Buy |
154,016
+52,856
| +52% | +$201K | ﹤0.01% | 3107 |
|
|
2021
Q2 | $430K | Buy |
101,160
+21,829
| +28% | +$94K | ﹤0.01% | 3155 |
|
|
2021
Q1 | $401K | Buy |
79,331
+44,469
| +128% | +$259K | ﹤0.01% | 3311 |
|
|
2020
Q4 | $184K | Buy |
34,862
+14,385
| +70% | +$82.4K | ﹤0.01% | 3805 |
|
|
2020
Q3 | $108K | Sell |
20,477
-2,741
| -12% | -$15.8K | ﹤0.01% | 4214 |
|
|
2020
Q2 | $126K | Buy |
23,218
+9,348
| +67% | +$49.6K | ﹤0.01% | 4364 |
|
|
2020
Q1 | $52K | Sell |
13,870
-28,260
| -67% | -$147K | ﹤0.01% | 5208 |
|
|
2019
Q4 | $284K | Buy |
42,130
+21,132
| +101% | +$159K | ﹤0.01% | 4763 |
|
|
2019
Q3 | $167K | Sell |
20,998
-5,546
| -21% | -$49.4K | ﹤0.01% | 5101 |
|
|
2019
Q2 | $256K | Buy |
26,544
+14,451
| +119% | +$152K | ﹤0.01% | 4889 |
|
|
2019
Q1 | $100K | Buy |
12,093
+7,373
| +156% | +$64.3K | ﹤0.01% | 5361 |
|
|
2018
Q4 | $39K | Sell |
4,720
-10,221
| -68% | -$102K | ﹤0.01% | 5599 |
|
|
2018
Q3 | $187K | Buy |
14,941
+12,075
| +421% | +$121K | ﹤0.01% | 5054 |
|
|
2018
Q2 | $23K | Sell |
2,866
-5,310
| -65% | -$54.9K | ﹤0.01% | 6104 |
|
|
2018
Q1 | $83K | Buy |
8,176
+2,615
| +47% | +$26.1K | ﹤0.01% | 5520 |
|
|
2017
Q4 | $36K | Buy |
5,561
+4,373
| +368% | +$29K | ﹤0.01% | 5950 |
|
|
2017
Q3 | $8K | Buy |
1,188
+914
| +334% | +$4.86K | ﹤0.01% | 6234 |
|
|
2017
Q2 | $1K | Buy |
274
+21
| +8% | +$118 | ﹤0.01% | 6510 |
|
|
2017
Q1 | $2K | Sell |
253
-2,205
| -90% | -$13.3K | ﹤0.01% | 6484 |
|
|
2016
Q4 | $15K | Buy |
2,458
+2,222
| +942% | +$15.7K | ﹤0.01% | 5753 |
|
|
2016
Q3 | $2K | Buy |
+236
| New | +$1.59K | ﹤0.01% | 6251 |
|
|
2015
Q3 | – | Sell |
-1,800
| Closed | -$5K | – | 6961 |
|
|
2015
Q2 | $5K | Buy |
+1,800
| New | +$7.11K | ﹤0.01% | 6449 |
|
Other funds holding MNOV
EWM
VCM
VFT
Barclays's MNOV Position: Q1 2026 in Review
Barclays increased its MediciNova (MNOV) stake by 313% in Q1 2026, buying an estimated $187K and bringing the position to 162,900 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #3628.
Barclays first reported a position in MNOV in Q2 2015 and has held it in 40 quarters since. The position peaked at $584K in Q3 2021. 30 funds tracked by Wall St. Rank hold MNOV as of Q1 2026.
- Barclays held 162,900 shares of MediciNova worth $223K as of Q1 2026.
- Barclays bought 123,500 MediciNova shares in Q1 2026, an estimated $187K.
- MediciNova made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3628 holding.
- Barclays first reported a position in MediciNova in Q2 2015 and has held it in 40 quarters since.
- Barclays's MediciNova position peaked at $584K in Q3 2021.
- 30 funds tracked by Wall St. Rank held MediciNova as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.